Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : OSE Immunotherapeutics SA
Deal Size : Undisclosed
Deal Type : Collaboration
OSE Immunotherapeutics forms Strategic Collaboration on Novel mRNA Tech
Details : OSE will develop novel RNA therapeutics and delivery methods to fine-tune immune responses in inflammatory disorders and autoimmune diseases, leveraging the advantages of RNA-based therapy.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : OSE Immunotherapeutics SA
Deal Size : Undisclosed
Deal Type : Collaboration